# ImmunityBio

Source: https://onco.cc/companies/immunitybio/  
OnCo record `immunitybio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ImmunityBio makes Anktiva, the IL-15 superagonist approved with BCG for bladder cancer in 2024.

## Summary

ImmunityBio, based in San Diego and listed as IBRX, makes Anktiva, or nogapendekin alfa inbakicept, the IL-15 superagonist approved with BCG for bladder cancer in 2024. The approval followed a long regulatory path that included a complete response letter in 2023, and the company also runs natural killer cell and vaccine programmes. OnCo links it to bladder and urothelial cancer, to the nogapendekin alfa inbakicept drug record, and to the idea of off-the-shelf natural killer cells to sweep up residual disease. Whether an IL-15 agonist can extend beyond BCG-unresponsive bladder cancer into other tumours is the open question its pipeline is built around. Anktiva has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-07
- Also known as: Altor BioScience
- HQ: San Diego, CA
- Type: biotech
- Website: https://immunitybio.com
- Ticker: IBRX

## Sources

- Official website: https://immunitybio.com

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- drugs: [Aldoxorubicin](https://onco.cc/drugs/aldoxorubicin/), [CD19 t-haNK](https://onco.cc/drugs/cd19-t-hank/), [Nogapendekin alfa inbakicept](https://onco.cc/drugs/nogapendekin-alfa/)
- trials: [A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In P](https://onco.cc/trials/nct06710288/), [A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer](https://onco.cc/trials/nct02138734/), [Aldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma](https://onco.cc/trials/aldoxorubicin-phase-3-sts/), [Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In](https://onco.cc/trials/nct06745908/), [Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer](https://onco.cc/trials/nct04390399/), [First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07355205/), [N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma](https://onco.cc/trials/nct06061809/), [QUILT 3.032](https://onco.cc/trials/quilt-3-032/), [QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors](https://onco.cc/trials/nct03228667/), [Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma](https://onco.cc/trials/nct07125872/)
- ideas: [Off-the-shelf natural killer cells to sweep up residual disease](https://onco.cc/ideas/idea-bio2-nk-cells-for-mrd/)

---
JSON: https://onco.cc/api/v1/entities/immunitybio.json